Magnetocardiography Study for Amyloidosis Disease Detection and Treatment Monitoring
This study observes how magnetocardiography can help detect and monitor amyloidosis disease, by comparing its effectiveness to electrocardiogram and measuring areas under the curve.
Data Collection
Collected from today forward - ProspectiveAmyloidosis+1
+ Metabolic Diseases
+ Nutritional and Metabolic Diseases
Cohort
Tracking disease incidence in order to identify risk factors and understand disease progression over time.Summary
Study start date: December 3, 2025
Actual date on which the first participant was enrolled.This study focuses on using a technique called magnetocardiography (MCG) to help diagnose and track the progression of amyloidosis, a condition where abnormal proteins build up in organs and tissues. The goal is to see how well MCG works compared to other methods like the electrocardiogram (ECG), which is commonly used. By finding better ways to detect and monitor this disease, the study hopes to improve the management and care of those affected by amyloidosis. Participants in this study will undergo magnetocardiography, a non-invasive procedure that records the magnetic signals of the heart. The results from these tests are compared to those from traditional ECGs to determine the accuracy and usefulness of MCG in identifying changes related to amyloidosis. This could potentially offer a new, more effective way of tracking the disease over time, ensuring patients receive timely and appropriate treatment adjustments.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.500 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Cohort
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria 1. Age ≥ 18 years on the date of consent 2. Ability for participant to comply with study requirements 3. Written informed consent Exclusion Criteria 1. Pregnant or breastfeeding 2. Having an active atrial fibrillation episode as seen on most current 12-lead ECG 3. Active thoracic metal implants (including pacemaker, insertable cardiac monitor, or internal defibrillator). 4. External electrical pads or devices (e.g. Pacer pads, ECG electrodes, heart rate patch), that must remain on patient's chest during MCG scan 5. Inability to lie down in a supine/inclined position and stay still on the examination bed 6. Clinical conditions that in the opinion of the Investigator would compromise the safety of the patient or ability to complete the protocol
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.Study Objectives
Primary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location